Published Online
on July 19, 2004

A more recent version of this article appeared on August 10, 2004

This Article Full Text (PDF) All Versions of this Article: 110/6/692    most recent 01.CIR.0000137831.08683.E1v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liao, Y. Articles by Kitakaze, M. Search for Related Content PubMed PubMed Citation Articles by Liao, Y. Articles by Kitakaze, M. Related Collections Congestive Remodeling Cardiovascular Pharmacology Animal models of human disease Hypertrophy Related Article

Submitted on September 4, 2003
Revised on May 6, 2004
Accepted on May 11, 2004

Celiprolol, A Vasodilatory -Blocker, Inhibits Pressure Overload-Induced Cardiac Hypertrophy and Prevents the Transition to Heart Failure via Nitric Oxide-Dependent Mechanisms in Mice

Yulin Liao MD, Masanori Asakura MD, PhD, Seiji Takashima MD, PhD, Akiko Ogai BS, Yoshihiro Asano MD, PhD, Yasunori Shintani MD, Tetsuo Minamino MD, PhD, Hiroshi Asanuma MD, PhD, Shoji Sanada MD, PhD, Jiyoong Kim MD, Soichiro Kitamura MD, PhD, Hitonobu Tomoike MD, PhD, Masatsugu Hori MD, PhD^*, and Masafumi Kitakaze MD, PhD

From the Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Osaka, Japan (Y.L., M.A., S.T., Y.A., Y.S., T.M., H.A., S.S., M.H.); and the Cardiovascular Division of Medicine, National Cardiovascular Center, Suita, Osaka, Japan (J.K., A.O., S.K., H.T., M.K.).

^* To whom correspondence should be addressed. E-mail: kitakaze{at}zf6.so-net.ne.jp.

Background--The blockade of -adrenergic receptors reduces both mortality and morbidity in patients with chronic heart failure, but the cellular mechanism remains unclear. Celiprolol, a selective ₁-blocker, was reported to stimulate the expression of endothelial NO synthase (eNOS) in the heart, and NO levels have been demonstrated to be related to myocardial hypertrophy and heart failure. Thus, we aimed to clarify whether celiprolol attenuates both myocardial hypertrophy and heart failure via the NO-signal pathway.

Methods and Results--In rat neonatal cardiac myocytes, celiprolol inhibited protein synthesis stimulated by either isoproterenol or phenylephrine, which was partially suppressed by N^G-nitro-L-arginine methyl ester (L-NAME). Four weeks after transverse aortic constriction (TAC) in C57BL/6 male mice, the ratio of heart weight to body weight (mg/g) (8.70±0.42 in TAC, 6.61±0.44 with celiprolol 100 mg · kg^-1 · d^-1 PO, P<0.01) and the ratio of lung weight to body weight (mg/g) (10.27±1.08 in TAC, 7.11±0.70 with celiprolol 100 mg · kg^-1 · d^-1 PO, P<0.05) were lower and LV fractional shortening was higher in the celiprolol-treated groups than in the TAC group. All of these improvements were blunted by L-NAME. Celiprolol treatment significantly increased myocardial eNOS and activated phosphorylation of eNOS. Myocardial mRNA levels of natriuretic peptide precursor type B and protein inhibitor of NO synthase, which were increased in the TAC mice, were decreased in the celiprolol-treated mice.

Conclusions--These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure. These effects are mediated by a selective ₁-adrenergic receptor blockade and NO-dependent pathway.

Key words: receptors, adrenergic, beta • heart failure • hypertrophy • nitric oxide

Related Article:

Circulation 2004 110: 643. [Extract] [Full Text]

This article has been cited by other articles:

				B. Yoo, A. Lemaire, S. Mangmool, M. J. Wolf, A. Curcio, L. Mao, and H. A. Rockman {beta}1-Adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1377 - H1386. [Abstract] [Full Text] [PDF]

				H. Sasaki, H. Asanuma, M. Fujita, H. Takahama, M. Wakeno, S. Ito, A. Ogai, M. Asakura, J. Kim, T. Minamino, et al. Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase Circulation, May 19, 2009; 119(19): 2568 - 2577. [Abstract] [Full Text] [PDF]

				A. Maffei, A. Di Pardo, R. Carangi, P. Carullo, R. Poulet, M. T. Gentile, C. Vecchione, and G. Lembo Nebivolol Induces Nitric Oxide Release in the Heart Through Inducible Nitric Oxide Synthase Activation Hypertension, October 1, 2007; 50(4): 652 - 656. [Abstract] [Full Text] [PDF]

				D. Juric, P. Wojciechowski, D. K. Das, and T. Netticadan Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2138 - H2143. [Abstract] [Full Text] [PDF]

				Y. Liao, S. Takashima, N. Maeda, N. Ouchi, K. Komamura, I. Shimomura, M. Hori, Y. Matsuzawa, T. Funahashi, and M. Kitakaze Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism Cardiovasc Res, September 1, 2005; 67(4): 705 - 713. [Abstract] [Full Text] [PDF]

				Y. Liao, M. Asakura, S. Takashima, A. Ogai, Y. Asano, H. Asanuma, T. Minamino, H. Tomoike, M. Hori, and M. Kitakaze Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice Cardiovasc Res, March 1, 2005; 65(4): 879 - 888. [Abstract] [Full Text] [PDF]

				G. W. Booz Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System Hypertension, March 1, 2005; 45(3): 341 - 346. [Abstract] [Full Text] [PDF]